Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00342875 · ClinicalTrials.gov registry record
The New England Bladder Cancer Study
A clinical trial of Bladder Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 2,681
- Enrollment target
- 1
- Study location
NCT00342875 is a study of Bladder Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 2,681 participants, below the 12,738-participant average among 175 other Bladder Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00342875, a study of Bladder Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 2,681 participants
- Enrollment target
- 1
- Study location
Study Summary
Data from the new cancer atlas covering the period 1974 1994 indicates that deaths from bladder cancer among white men and women are elevated in the northeastern United States, particularly the northern parts of New England. The reason for these elevated rates of incidence of and deaths from bladder cancer is unknown. Only part of the excess risk can be explained by exposure to the textile and leather industries. The purpose of this study is to determine the factors that contribute to the high rates of incidence of and death from bladder cancer in northern New England. The main objectives are to: * estimate the risk of developing bladder cancer associated with inorganic arsenic in drinking water, other water contaminants, tobacco use, occupational exposures, residential proximity to industrial sites, dietary factors, ethnicity, and use of wood-burning stoves. * estimate the extent to which water containing inorganic arsenic explains the increased rates of bladder cancer. * estimate the extent to which exposure to other risk factors explains the increased rates. * evaluate risk of bladder cancer according to genetic factors. * examine interactions of these factors with tobacco use, occupational exposure, and environmental exposure to arsenic and other compounds. All people ages 30 79 with confirmed cases of bladder cancer will be eligible for the study. Twelve hundred people with bladder cancer and twelve hundred individuals with no previous bladder cancer will be included. After potential participants are recruited and agreement is obtained over the telephone, they will complete a calendar and collect toenail clippings prior to the home interview. During the home visit, an investigator will administer a computer-assisted personal interview, collect drinking water samples and the clippings, and obtain a global positioning satellite reading. Other biological samples, such as saliva samples, urine, and blood, may be requested. Private wells at any previous homes o
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,681 participants |
| Start Date | 2002-03-01 |
| Est. Completion | 2020-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00342875
The ClinicalTrials.gov registry entry for NCT00342875 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,681 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,738-participant average among 175 other Bladder Cancer trials with a reported enrollment target (79% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT00342875 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00342875 about?
NCT00342875 is a clinical study titled "The New England Bladder Cancer Study". Data from the new cancer atlas covering the period 1974 1994 indicates that deaths from bladder cancer among white men and women are elevated in the northeastern United States, particularly the northern parts of New England. The reason for these elevated rates of incidence of and deaths from bladder...
What is the current status of trial NCT00342875?
This trial is currently completed. The enrollment target is 2,681 participants. The study started on 2002-03-01. Estimated completion is 2020-07-14.
What conditions does trial NCT00342875 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT00342875?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00342875 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.